Journal of Applied Physiology Millar Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 80: 191-197, 1996;
8750-7587/96 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cuiper, L. L.
Right arrow Articles by Christman, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuiper, L. L.
Right arrow Articles by Christman, B. W.

Journal of Applied Physiology, Vol 80, Issue 1 191-197, Copyright © 1996 by American Physiological Society

ARTICLES

Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2

L. L. Cuiper, P. V. Price and B. W. Christman
Center for Lung Research, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2650, USA.

Chronic administration of prostacyclin (PGI2) improves hemodynamics in patients with primary pulmonary hypertension, but abrupt cessation of infusion can cause severe dyspnea of unknown etiology. We hypothesized that the discontinuation of PGI2 results in platelet activation, thromboxane A2 production, and increased pulmonary vascular tone. To test this, six sheep with indwelling catheters were monitored during infusion of PGI2 and after its cessation. Infusion of PGI2 caused a reduction in mean systemic arterial pressure (MAP) and systemic (SVR) and pulmonary vascular resistances (PVR), a rise in cardiac output (CO), and no change in pulmonary arterial or pulmonary capillary wedge pressure (PCWP). After discontinuation of PGI2, MAP and SVR rebounded to 30 and 67% above baseline, respectively, and PVR rose 26%. CO was depressed 23% within 10 min, and PCWP nearly doubled after stoppage of the drug. Concurrent treatment with a cyclooxygenase inhibitor did not attenuate these responses. 11-Dehydro-thromboxane B2 levels were not elevated during infusion or after cessation of PGI2. We conclude that the abrupt cessation of PGI2 infusion leads to systemic and pulmonary hypertension and transient cardiac dysfunction not mediated by cyclooxygenase metabolites of arachidonic acid.


This article has been cited by other articles:


Home page
 Poult. Sci.Home page
R. F. Wideman, O. T. Bowen, and G. F. Erf
Broiler pulmonary hypertensive responses during lipopolysaccharide-induced tolerance and cyclooxygenase inhibition
Poult. Sci., January 1, 2009; 88(1): 72 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Kataoka, N. Nagaya, T. Satoh, T. Itoh, S. Murakami, T. Iwase, Y. Miyahara, S. Kyotani, Y. Sakai, K. Kangawa, et al.
A Long-Acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1575 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Archer and S. Rich
Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress"
Circulation, November 28, 2000; 102(22): 2781 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
I. M. Robbins, L. L. Cuiper, C. M. Stein, A. J. J. Wood, H. B. He, R. Parker, and B. W. Christman
Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep
J Appl Physiol, August 1, 1998; 85(2): 731 - 737.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online